Genetics of cancer therapy|induced cardiomyopathy

Genetic Variants Associated With Cancer Therapy–Induced ...

Our findings show that variants in cardiomyopathy genes contribute to CCM susceptibility among adult and pediatric patients with cancer. · The ...

Genetics of Cancer Therapy-Associated Cardiotoxicity - PMC - NCBI

Pathogenic variants in the genes encoding proteins that comprise sarcomeres also contribute to cardiomyopathy following cancer therapies.

Genetics of cancer therapy-induced cardiomyopathy - Nature

Patients with chemotherapy-induced cardiomyopathy have a high prevalence of rare variants of cardiomyopathy-related genes, in particular ...

Genetic Variants Associated With Cancer Therapy-Induced ...

Background: Cancer therapy-induced cardiomyopathy (CCM) is associated with cumulative drug exposures and preexisting cardiovascular disorders.

Variants in structural cardiac genes in patients with cancer therapy ...

Variants in cardiomyopathy genes have been identified in patients with cancer therapy-related cardiac dysfunction (CTRCD), suggesting a ...

Genetics of cancer therapy-associated cardiotoxicity

Pathogenic variants in the genes encoding proteins that comprise sarcomeres also contribute to cardiomyopathy following cancer therapies.

Genetics of cancer therapy-associated cardiotoxicity - ScienceDirect

Pathogenic variants in the genes encoding proteins that comprise sarcomeres also contribute to cardiomyopathy following cancer therapies. Furthermore, genetic ...

Genetic Factors Involved in Cardiomyopathies and in Cancer - MDPI

Cancer therapy-induced cardiomyopathy (CCM) manifests as left ventricular (LV) dysfunction and heart failure (HF). It is associated withparticular ...

Genetic predisposition in chemotherapy‐induced cardiomyopathy in ...

Further investigation with genetic testing revealed a likely pathogenic variant in the TNNT2 gene, suggesting a genetic predisposition to CTRCD.

Potential Gene Association Studies of Chemotherapy-Induced ...

Currently, genetic methods have been used to detect patients with high risk of chemotherapy-induced cardiotoxicity (CIC), and our study ...

Genetic Variants Associated With Cancer Therapy–Induced ...

Cancer therapy–induced cardiomyopathy (CCM) is associated with cumulative drug exposures and preexisting cardiovascular disorders. These ...

Genetics of cancer therapy-associated cardiotoxicity

Survivors of cancer therapies have life-long increased risks for heart disease. ... Both common and rare damaging gene variants convey cardiotoxicity risks.

Genetics of Anthracycline Cardiomyopathy in Cancer Survivors ...

Anthracyclines are an integral part of chemotherapy regimens used to treat a variety of childhood-onset and adult-onset cancers. However, the development of ...

Genetics may play a role in developing cancer therapy-induced ...

"Our study is the first to consider the association between rare genetic variants in a large set of cardiomyopathy genes and the occurrence of ...

Genetic variant linked to chemotherapy-induced cardiomyopathy

The same genetic variants that have been uncovered in patients with two other types of cardiomyopathy are also present in an uncommonly high ...

Genetics of Anthracycline-Associated Cardiotoxicity - Frontiers

Genetic Variants Associated With Cancer Therapy-Induced Cardiomyopathy. ... genetics, genetic testing, cardio-oncology, anthracycline.

Genetic Susceptibility for Anthracycline-Induced Cardiomyopathy

Anthracyclines are a class of chemotherapeutic agents widely used in the treatment of various types of cancer. However, anthracycline-induced ...

Genetic Variants Associated with Therapy-Related Cardiomyopathy ...

Childhood cancer survivors of African ancestry are at higher risk of cardiomyopathy than those of European ancestry, and a novel locus at 1p13.2 is.

Genetic Testing in Evaluating Risk of Anthracycline Cardiomyopathy

Childhood cancer survivors are at increased risk of cardiac dysfunction following anthracycline therapy, and those who subsequently develop ...

Genetic Crosstalk in Cancer-Therapy-Induced Cardiomyopathy

A genetic study links cancer-therapy-induced and dilated cardiomyopathies and signals how identification of genetic risk factors may help ...